Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Kadam Amare PS, Jain H, Nikalje S, Sengar M, Menon H, Inamdar N, Subramanian PG, Gujral S, Shet T, Epari S, Nair R.

Indian J Med Res. 2016 Oct;144(4):536-543. doi: 10.4103/0971-5916.200890.

2.

Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma.

Xu L, Fan S, Zhao J, Zhou P, Chu S, Luo J, Wen Q, Chen L, Wen S, Wang L, Shi L.

Diagn Pathol. 2017 Jan 7;12(1):2. doi: 10.1186/s13000-016-0589-9.

3.

Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity.

Gardella KA, Muro I, Fang G, Sarkar K, Mendez O, Wright CW.

Oncotarget. 2016 Mar 8;7(10):10710-22. doi: 10.18632/oncotarget.7539.

4.

Multiple Myeloma: Treatment is Getting Individualized.

Agarwal MB.

Indian J Hematol Blood Transfus. 2016 Mar;32(1):3-9. doi: 10.1007/s12288-015-0575-5. Epub 2015 Jul 26. Review.

5.

The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.

Yu W, Guo R, Qu X, Qiu H, Li J, Zhang R, Chen L.

Onco Targets Ther. 2016 Jan 12;9:295-302. doi: 10.2147/OTT.S95381. eCollection 2016.

6.

Regulation of Transient Site-specific Copy Gain by MicroRNA.

Black JC, Zhang H, Kim J, Getz G, Whetstine JR.

J Biol Chem. 2016 Mar 4;291(10):4862-71. doi: 10.1074/jbc.M115.711648. Epub 2016 Jan 11.

7.

Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive.

Mishra S, Whetstine JR.

Mol Cell Biol. 2016 Jan 11;36(7):1050-63. doi: 10.1128/MCB.00652-15. Review.

8.

Novel strategies to target the ubiquitin proteasome system in multiple myeloma.

Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2016 Feb 9;7(6):6521-37. doi: 10.18632/oncotarget.6658. Review.

9.

Hypoxia drives transient site-specific copy gain and drug-resistant gene expression.

Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP, Song B, Andriani G, Joung JK, Iliopoulos O, Montagna C, Pillai S, Getz G, Whetstine JR.

Genes Dev. 2015 May 15;29(10):1018-31. doi: 10.1101/gad.259796.115.

10.
11.

The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma.

Prideaux SM, Conway O'Brien E, Chevassut TJ.

Bone Marrow Res. 2014;2014:526568. doi: 10.1155/2014/526568. Epub 2014 Sep 11.

12.

Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.

Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradov√° L, Hajek R, Kuglik P.

Biomed Res Int. 2014;2014:209670. doi: 10.1155/2014/209670. Epub 2014 Jun 2.

13.

The genetic architecture of multiple myeloma.

Prideaux SM, Conway O'Brien E, Chevassut TJ.

Adv Hematol. 2014;2014:864058. doi: 10.1155/2014/864058. Epub 2014 Apr 3. Review.

14.

Cks1: Structure, Emerging Roles and Implications in Multiple Cancers.

Khattar V, Thottassery JV.

J Cancer Ther. 2013 Oct 1;4(8):1341-1354.

15.

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.

Abdi J, Chen G, Chang H.

Oncotarget. 2013 Dec;4(12):2186-207. Review. Erratum in: Oncotarget. 2015 Apr 10;6(10):7364. Oncotarget. 2015 Apr 10;6(10):7364.

16.

A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.

Chung TH, Mulligan G, Fonseca R, Chng WJ.

PLoS One. 2013 Jun 20;8(6):e66361. doi: 10.1371/journal.pone.0066361. Print 2013.

17.

In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.

Debes Marun CS, Belch AR, Pilarski LM.

Am J Hematol. 2012 Jun;87(6):579-87. doi: 10.1002/ajh.23194. Epub 2012 Apr 12.

18.

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.

Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Barlogie B, Shaughnessy JD Jr.

Int J Hematol. 2011 Oct;94(4):321-33. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15. Review.

19.

CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.

Chang H, Jiang N, Jiang H, Saha MN, Qi C, Xu W, Reece D.

Haematologica. 2010 Sep;95(9):1542-7. doi: 10.3324/haematol.2010.022210. Epub 2010 Apr 26.

20.

CKS proteins protect mitochondrial genome integrity by interacting with mitochondrial single-stranded DNA-binding protein.

Radulovic M, Crane E, Crawford M, Godovac-Zimmermann J, Yu VP.

Mol Cell Proteomics. 2010 Jan;9(1):145-52. doi: 10.1074/mcp.M900078-MCP200. Epub 2009 Sep 28.

Supplemental Content

Support Center